BioLineRx Ltd ADR

BioLineRx reported Q3 2025 EPS of $0 (forecast -$0.08) and revenue of $0.4m versus $4.62m expected, a revenue shortfall of 90.69%. The stock fell 3.85% to $3.25 after the results; net loss narrowed to $1m (prior year $5.8m). The company holds $25.2m in cash (sufficient through H1 2027) and plans a Phase‑1/2a study for GlyxOne in early 2026 with Phase‑1 data expected in H1 2027. » More on de.investing.com

BioLineRx shares rose 8.4% in premarket trading after development partner Hemispherian received an approval notice from the US Patent Office for GLIX1. The patent covers the use of GLIX1 in cancers where cytidine deaminase is not overexpressed above a defined threshold, a characteristic thought to be present in more than 90% of tumors. The protection secures intellectual property until 2040 (with a possible extension of up to five years), and the partners plan a Phase 1/2a study in glioblastoma in early 2026 as well as preclinical studies for additional solid tumors. » More on de.investing.com